Filing summary
Entity and period: The supplied filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, covering three and six months ended on that date. This does not match the request metadata identifying Edesa Biotech, Inc.; the filing text identifies Stellar as the registrant. Amounts below are U.S. dollars.
Business context
Stellar develops, manufactures and commercializes Keyhole Limpet Hemocyanin (KLH) for biotechnology, pharmaceutical, immunotherapy and immunodiagnostic uses. The company changed its fiscal year-end from August 31 to September 30, so comparative results were recast to calendar quarters.
Financial performance and position
| Metric | Three months ended March 31, 2015 | Six months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $187,627 | $400,288 | $114,371 quarterly; $173,196 six-month |
| Net loss | $426,164 | $1,769,641 | $1,433,854 quarterly; $7,011,044 six-month |
| Basic loss per share | $0.01 | $0.02 | $0.02 quarterly; $0.09 six-month |
| Operating cash used | Not provided separately | $2,581,458 | $2,560,177 six-month |
- Six-month revenue comprised product sales of $295,288 and contract services of $105,000; there was no grant revenue. Product sales were $58,456 and contract services $87,000 in the prior-year six-month period.
- Six-month expenses were $2,915,336, down from $3,309,438. Research and development fell to $700,405 from $1,281,321; general and administrative expense increased to $1,727,834 from $1,667,800. Production and aquaculture costs increased to $410,640 from $294,913.
- Cash and cash equivalents were $11,145,555 at March 31, 2015, down $2,624,398 from September 30, 2014. Working capital was $8,538,408, including a $2,489,934 current warrant liability. Total assets were $11,826,615 and total liabilities $2,903,875.
- No conventional borrowing or interest-bearing debt is reported in the presented balance sheet. Liabilities include warrant liabilities; accounts payable and accrued liabilities were $413,941. Six-month investing activities provided $367,119, including $424,813 from short-term investment maturities; financing activities provided $28,719.
- The filing reports no gross-margin measure. Revenue was below the combined six-month contract-service and production/aquaculture costs shown.
Changes, outlook and risks
- The six-month net loss improved substantially year over year, primarily because the warrant-liability fair-value effect changed from a $3,694,588 loss in 2014 to a $1,201,332 gain in 2015. These are noncash valuation changes and materially affect reported earnings.
- Management attributed revenue growth mainly to increased customer demand, product sales under supply agreements and custom manufacturing, plus collaboration-related services. R&D spending declined as the company shifted emphasis from internal research and process development toward manufacturing.
- Foreign-exchange loss increased to $468,658 for the six months, largely reflecting unfavorable exchange rates on Canadian cash holdings; the cash-realized portion was $7,968. Cash was also reduced by a $438,778 exchange-rate effect.
- Management said current financial resources were adequate for at least 12 months at the current operating level and sufficient for anticipated obligations and R&D spending. It also expected continued losses, noted possible need for additional capital, and said future financing could include product revenue, grants, equity or debt securities, and strategic collaborations. There is no assurance financing will be available on acceptable terms.
- Customer concentration is significant: three customers generated approximately 82% of product sales and contract-services revenue in the six-month period. The company disclosed no material legal proceedings outside the ordinary course and no material changes to previously disclosed risk factors.
- Commitments include approximately $138,000 in future minimum lease payments, about $70,000 of signed manufacturing/consultant commitments, and estimated time-and-materials contractor obligations of about $85,000. The KLH-related C. diff license includes contingent development/financing milestones of up to $6.02 million and sales milestones of up to $57.025 million; no milestones were met in the reported six months.
Important facts for investors to verify
- Confirm the intended issuer: this source is Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.
- Assess cash runway against operating cash use, continuing losses, and management’s stated potential need for further financing.
- Separate recurring operating performance from noncash warrant-liability remeasurement and foreign-exchange effects.
- Verify whether revenue growth and customer concentration persist, particularly given the filing’s warning that revenue is volatile.
- Review warrant terms, expirations and potential dilution, as well as the contingent license milestones and collaboration’s lack of an assured future commercial supply agreement.